Prilenia is a clinical-stage biotech company developing pridopidine, a treatment that activates the sigma-1 receptor to restore impaired neural pathways in patients with Huntington’s disease and amyotrophic lateral sclerosis (ALS). The company addresses the urgent need for effective therapies in neurodegenerative and neurodevelopmental disorders, aiming to improve patient outcomes and quality of life.
Funding
$143.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MVSCFounders
Product
Problem
Huntington's disease and amyotrophic lateral sclerosis (ALS) are neurodegenerative diseases with limited effective treatment options, leading to impaired neural pathways and reduced quality of life for patients. There is an urgent need for therapies that can restore these impaired pathways and improve patient outcomes.
Solution
Prilenia is developing pridopidine, a clinical-stage treatment designed to activate the sigma-1 receptor (S1R) in the brain. Activation of S1R has shown promise in restoring neural pathways impaired by neurodegenerative diseases. By targeting S1R, Prilenia aims to address the underlying mechanisms of Huntington's disease and ALS, potentially slowing disease progression and alleviating symptoms. The company is dedicated to advancing research and uncovering new possibilities for patients and their families affected by these conditions.
Target Audience
The primary target audience includes patients diagnosed with Huntington's disease or amyotrophic lateral sclerosis (ALS), as well as their families and caregivers.
Features
- Pridopidine: A selective sigma-1 receptor (S1R) agonist in clinical development.
- Focus on restoring impaired neural pathways in neurodegenerative diseases.
- Potential to slow disease progression and alleviate symptoms.